First Episealer® surgery performed in Asia
Episurf Medical (Nasdaq: EPIS B) today announces that the first Episealer® surgery in Asia has been performed at a Hong Kong clinic. The surgery had been postponed due to Covid-19, but now, it was possible to perform the surgery.
“We are pleased with the outcome of the first Episealer® surgery in Hong Kong and Asia. The first surgeries in both Asia and in the US have been performed under exceptional circumstances given the current pandemic, without representatives from Episurf in Europe at the site. But all went very well in both cases, and we look forward to the next steps in these important regions”, says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.